Curative Intent Treatment of Stage III Non–Small Cell Lung Cancer

2018 ◽  
pp. 83-98
Author(s):  
Sameer K. Nath ◽  
Trevor J. Bledsoe ◽  
Roy H. Decker
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Curative Intent

scholarly journals A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer

2021 ◽  
Vol 28 (3) ◽  
pp. 1618-1629
Author(s):  
Anthony Brade ◽  
Kevin Jao ◽  
Simon Yu ◽  
Parneet Cheema ◽  
Sarah Doucette ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Standard Of Care ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Curative Intent ◽  
Wide Range ◽  
Stage Iii Nsclc

Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogenous group of patients with regards to patient fitness and tumour size and distribution, resulting in a wide range of treatment goals and therapy options. Curative-intent multimodality treatment should be considered in all patients with stage III NSCLC. For patients with unresectable disease who are fit, have adequate lung function, and have a disease that can be encompassed within a radical radiation volume, concurrent chemoradiation therapy (cCRT) is the standard of care and can produce cure rates of 20–30%. Recently, consolidation immunotherapy with durvalumab has been recognized as the standard of care following cCRT based on significant improvement rates in overall survival at 4 years. The large heterogeneity of the stage III NSCLC population, along with the need for extensive staging procedures, multidisciplinary care, intensive cCRT, and now consolidation therapy makes the delivery of timely and optimal treatment for these patients complex. Several logistical, communication, and education factors hinder the delivery of guideline-recommended care to patients with stage III unresectable NSCLC. This commentary discusses the potential challenges patients may encounter at different points along their care pathway that can interfere with delivery of curative-intent therapy and suggests strategies for improving care delivery.

Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent

2020 ◽  
Vol 21 (3) ◽  
pp. e130-e141 ◽  
Author(s):  
Stephanie R. Rice ◽  
Melissa A.L. Vyfhuis ◽  
Katherine A. Scilla ◽  
Whitney M. Burrows ◽  
Neha Bhooshan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Independent Predictor ◽  
Small Cell ◽  
Stage Iii ◽  
Insurance Status ◽  
Small Cell Lung ◽  
Curative Intent

Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer

2002 ◽  
Vol 29 (3 Suppl 12) ◽  
pp. 10-16 ◽  
Author(s):  
Angela Davies ◽  
David R. Gandara ◽  
Primo Lara ◽  
Zelanna Goldberg ◽  
Peter Roberts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iii ◽  
Advanced Stage ◽  
Therapeutic Approaches ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document